Autres langues PTC Therapeutics, Inc.

Actions

PTCT

US69366J2006

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 19/04/2024			Varia. 5j.	Varia. 1 janv.
25,32 ^USD	+2,55 %		-4,16 %	-8,13 %

28/03	PTC Therapeutics demande à l'EMA une autorisation de mise sur le marché de la sépiaptérine pour le traitement de la phénylcétonurie	MT
28/03	PTC Therapeutics, Inc. annonce la soumission à l'EMA de l'AMM de la sépiaptérine pour le traitement de la PCU	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results	12/04
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results	11/04
PTC Therapeutics Seeks EMA Marketing Authorization for Sepiapterin for Phenylketonuria Treatment	28/03
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	28/03
PTC Therapeutics, Inc. Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	28/03
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency	20/03
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza? as a Treatment for AADC Deficiency	19/03
PTC Therapeutics Provides Key Regulatory Updates	19/03
PTC Therapeutics Shares Jump Following Q4 Results	01/03
PTC Therapeutics Q4 Loss Narrows, Sales Up; Sets Guidance; Shares Slump After-Hours	29/02
PTC Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
PTC Therapeutics: Q4 Earnings Snapshot	29/02
PTC Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	29/02
Earnings Flash (PTCT) PTC THERAPEUTICS Posts Q4 Revenue $307.1M, vs. Street Est of $317.9M	29/02
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	29/02
PTC Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
PTC Therapeutics to Participate at Upcoming Investor Conferences	27/02
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22/02
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	21/02
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results	15/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues PTC Therapeutics, Inc.

Actions

PTCT

US69366J2006

Autres langues

Filtres